Monogenic gene therapy for glaucoma and optic nerve injury  

作　　者：Chikako Harada Xiaoli Guo Takayuki Harada 

机构地区：[1]Visual Research Project,Tokyo Metropolitan Institute of Medical Science,Tokyo,Japan

出　　处：《Neural Regeneration Research》2025年第3期815-816,共2页中国神经再生研究（英文版）

基　　金：supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grants-in-Aid for Scientific Research (JP22K09804 to CH;JP21K09688 to XG;JP19KK0229, JP21H04786, JP21H02819 and JP21K18279 to TH);the Shiseido Female Researcher Science Grant (to XG);Mitsubishi Foundation;Takeda Science Foundation (to TH)。

摘　　要：The prevalence of glaucoma, the second leading cause of global blindness, is increasing due to aging populations. In glaucoma, degeneration of the optic nerve and retinal ganglion cells(RGCs) causes visual field defects and eventual blindness.

关 键 词：VISUAL GLAUCOMA DEGENERATION 

分 类 号：R775[医药卫生—眼科] R774.6[医药卫生—临床医学] R450